Anti-Mullarian Hormone As A Diagnostic Marker of Polycystic Ovary Syndrome

Abstract

Objective: To determine the utility of Anti-mullerian hormone (AMH) as a diagnostic marker of Polycystic ovarian syndrome (PCOS). Study Design: Comparative cross-sectional study Place and Duration of the Study: Department of Chemical Pathology and Endocrinology, Army Medical College Rawalpindi, Pakistan in collaboration with the Department of Gynaecology and Obstetrics, Pak-Emirates Military Hospital, Rawalpindi Pakistan from Jan 2019 to Jan 2020. Methodology: The study recruited 30 cases of PCOS and 30 age-matched Controls using Rotterdam criteria. Anti-mullerian hormone (AMH) and testosterone were measured for both the study groups. Results: Receiver operator curve (ROC) analysis confirmed the utility of anti-mullerian hormone in diagnosing patients with PCOS. The AUC was 0.754 with 95% CI (0.629-0.880). The optimal cut-off point was 3.22ng/mL (Sensitivity 80%, Specificity 66.7%). Conclusion: The AMH is appraised as an independent screening marker for PCOS patients. Using this single parameter can decrease the patient's inconvenience and financial burden on the health care system and the patient.